1. ADROPIN AS A POTENTIAL PROTECTIVE FACTOR OF METABOLIC COMPLICATIONS IN OBESE PREGNANT WOMEN WITH HYPERGLYCAEMIA DIAGNOSED IN EARLY PREGNANCY.
- Author
-
ADAMCZAK, L., MANTAJ, U., GUTAJ, P., SKRYPNIK, D., OZEGOWSKI, S., BOGDANSKI, P., and WENDER-OZEGOWSKA, E.
- Abstract
Adropin is a hormone which increases insulin sensitivity. It enhances the oxygenation of glucose in the muscles. The 91 obese pregnant women (BMI >30 kg/m2) with gestational diabetes mellitus (GDM) diagnosed in the first half of pregnancy has been recruited to the study group. The control group consisted of 10 age matched and homogeneous pregnant women with BMI <25 kg/m2. Blood samples were collected on visit V1 - between the 28th and 32nd week and on visit V2 - between the 37th and 39th week of gestation. The ELISA test was used to measure the adropin level. The results in the study group and the control group were compared. Blood samples were collected at the same visits. The median concentration of adropin was 442.2 pg/ml on V1 and 453.1 pg/ml on V2. The increase was significant (p<0.05). Results were significantly lower in the control group's patients, i.e. 57.0 pg/ml (p<0.001) on V1 and 107.9 pg/ml on V2 (p<0.001). The higher adropin level on the V1 and V2 visits were related to patients' lower BMI and better metabolic control. The increase in the adropin level in the third trimester may have been involved in the weight gain reduction, whereas better dietary adherence might have had a compensatory effect on increasing insulin resistance. However, the small control group is a limitation of this study. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF